An analysis of the effect of Oxaliplatin in inducing immunogenetic celldeath and improving the efficacy of checkpoint inhibitor on SGC-7901

Abstract

Previous studies demonstrated Oxaliplatin, a derivative of Cisplatin, to have anti-cancer properties in a Lewis Lung
Carcinoma (LLC). It can induce immunogenic cell death (ICD) in tumor cells and co-administrate with checkpoint
inhibitors to improve the therapeutic efficacy. This study aims to investigate Oxaliplatin’s effect on a different gastric
carcinoma, SGC-7901, and analyze the therapeutic efficacy of its co-administration with the checkpoint inhibitor. To
evaluate the immunogenic cell death (ICD) induced by Oxaliplatin in SGC-7901, flow cytometry, HMGB1, ATP release,
and immunoblotting were conducted. The effectiveness of Oxaliplatin was analyzed using a vaccination approach and
subcutaneous tumor models to observe tumour regression. PD-L1 mRNA and protein levels in SGC-7901 were also
examined. The therapeutic efficacy of Oxaliplatin in murine lung tumor models will be enhanced by co-administering
with aPD-L1. Cisplatin will be employed as a positive control, while PBS will be a negative control. The result of the
study will provide important insight into the experimental effectiveness of Oxaliplatin in SGC-7901, it also sets the
basis for future experimental, preclinical, and clinical studies of the drug. Future studies should focus on practicing the
actual experiment on the experimental effectiveness of Oxaliplatin in SGC-7901 and look for the applicability of the
effectiveness of Oxaliplatin on other tumor cells.